GT
KYNB

Glenmede Trust’s Kyntra Bio KYNB Stock Holding History

Glenmede Trust’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-302
Closed -$261K – 1285
2021
Q1 		$261K Buy
302
+4
+1% +$4.26K ﹤0.01% 1007
2020
Q4 		$276K Buy
298
+30
+11% +$31.5K ﹤0.01% 985
2020
Q3 		$275K Buy
268
+67
+33% +$72.1K ﹤0.01% 945
2020
Q2 		$203K Buy
+201
New +$187K ﹤0.01% 1004
2019
Q1 		– Sell
-9
Closed -$10 – 3090
2018
Q4 		$10 Buy
+9
New +$10.1K ﹤0.01% 2271
2018
Q3 		– Sell
-48
Closed -$74K – 1580
2018
Q2 		$74K Buy
+48
New +$62.6K ﹤0.01% 1336

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's KYNB Position: Q2 2021 in Review

Glenmede Trust sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 302 shares — an estimated $261K sold.

Glenmede Trust first reported a position in KYNB in Q2 2018 and held it in 6 quarters. The position peaked at $276K in Q4 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Glenmede Trust reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Glenmede Trust sold 302 Kyntra Bio shares in Q2 2021, an estimated $261K.
  • Glenmede Trust first reported a position in Kyntra Bio in Q2 2018 and held it in 6 quarters.
  • Glenmede Trust's Kyntra Bio position peaked at $276K in Q4 2020.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Glenmede Trust's 13F filing for Q2 2021, filed 16 Aug 2021.